References
- Dahia PL, Ross KN, Wright ME et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet.1(1), 72–80 (2005).
- Eisenhofer G, Huynh TT, Pacak K et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel–Lindau syndrome. Endocr. Relat. Cancer11(4), 897–911 (2004).
- Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab.90(4), 2110–2116 (2005).
- Goldstein RE, O’Neill JA Jr, Holcomb GW 3rd et al. Clinical experience over 48 years with pheochromocytoma. Ann. Surg.229(6), 755–764 (1999).
- Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur. J. Surg. Oncol.29(3), 278–283 (2003).
- Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res.63(17), 5615–5621 (2003).
- Gao B, Meng F, Bian W et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology68(2), 282–286 (2006).
- Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol.26(5), 551–566 (2002).
- Strong VE, Kennedy T, Al-Ahmadie H et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery143(6), 759–768 (2008).
- Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol.23(34), 8812–8818 (2005).
- Favier J, Kempf H, Corvol P, Gasc JM. Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Lett.462(1–2), 19–24 (1999).
- Ballester R, Marchuk D, Boguski M et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell63(4), 851–859 (1990).
- Califano D, Rizzo C, D’Alessio A et al. Signaling through Ras is essential for RET oncogene-induced cell differentiation in PC12 cells. J. Biol. Chem.275(25), 19297–19305 (2000).
- Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell8(2), 155–167 (2005).
- Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience147(4), 928–937 (2007).
- Powers JF, Tischler AS, Mohammed M, Naeem R. Microarray-based comparative genomic hybridization of pheochromocytoma cell lines from neurofibromatosis knockout mice reveals genetic alterations similar to those in human pheochromocytomas. Cancer Genet. Cytogenet.159(1), 27–31 (2005).
- Dahia PL. Evolving concepts in pheochromocytoma and paraganglioma. Curr. Opin. Oncol.18(1), 1–8 (2006).
- Dahia PL, Hao K, Rogus J et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res.65(21), 9651–9658 (2005).
- August C, August K, Schroeder S et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod. Pathol.17(9), 1119–1128 (2004).
- Cascon A, Ruiz-Llorente S, Rodriguez-Perales S et al. A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. Genes Chromosomes Cancer42(3), 260–268 (2005).
- Dannenberg H, Speel EJ, Zhao J et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am. J. Pathol.157(2), 353–359 (2000).
- Edstrom E, Mahlamaki E, Nord B et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am. J. Pathol.156(2), 651–659 (2000).
- Jarbo C, Buckley PG, Piotrowski A et al. Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int. J. Cancer118(5), 1159–1164 (2006).
- Aarts M, Dannenberg H, deLeeuw RJ et al. Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1–0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer45(1), 83–93 (2006).
- Brouwers FM, Eisenhofer G, Tao JJ et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J. Clin. Endocrinol. Metab.91(11), 4505–4509 (2006).
- Rao F, Keiser HR, O’Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension36(6), 1045–1052 (2000).
- Proye C, Fossati P, Fontaine P et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery100(6), 1154–1162 (1986).
- Eisenhofer G, Goldstein DS, Sullivan P et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab.90(4), 2068–2075 (2005).
- John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology53(4), 679–683 (1999).
- Thouennon E, Elkahloun AG, Guillemot J et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J. Clin. Endocrinol. Metab.92(12), 4865–4872 (2007).
- Yon L, Guillemot J, Montero-Hadjadje M et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J. Clin. Endocrinol. Metab.88(6), 2579–2585 (2003).
- Guillemot J, Barbier L, Thouennon E et al. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas. Ann. NY Acad. Sci.1073, 527–532 (2006).
- Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am. J. Pathol.161(4), 1235–1246 (2002).
- Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS111(4), 458–464 (2003).
- Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab.86(11), 5615–5619 (2001).
- Boltze C, Mundschenk J, Unger N et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J. Clin. Endocrinol. Metab.88(9), 4280–4286 (2003).
- Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr. Pathol.13(2), 99–110 (2002).
- Salmenkivi K, Arola J, Voutilainen R et al. Inhibin/activin β-subunit expression in pheochromocytomas favors benign diagnosis. J. Clin. Endocrinol. Metab.86(5), 2231–2235 (2001).
- Ohta S, Lai EW, Pang AL et al. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int. J. Cancer114(1), 139–143 (2005).
- Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase-α II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl. Immunohistochem. Mol. Morphol.8(4), 267–274 (2000).
- Salmenkivi K, Heikkila P, Haglund C, Louhimo J, Arola J. Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas. Histopathology43(1), 62–71 (2003).
- Petri BJ, Speel EJ, Korpershoek E et al. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod. Pathol.21(4), 407–413 (2008).
- Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab.91(3), 827–836 (2006).
- Amar L, Baudin E, Burnichon N et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab.92(10), 3822–3828 (2007).
- Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA292(8), 943–951 (2004).
- Brouwers FM, Elkahloun AG, Munson PJ et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann. NY Acad. Sci.1073, 541–556 (2006).
- Anouar Y, Yon L, Guillemot J et al. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Ann. NY Acad. Sci.1073, 533–540 (2006).
- Fränkel F. Ein Fall von doppelseitigem, völlig latent verlaufenen nebennierentumor und gleichzeitiger nephritis mit veränderungen am circulationsapparat und retinitis. Arch. Pathol. Anat. Physiol. Klin. Med.103, 244–263 (1886).